which work through the NLRP3 inflammasome,” explains Richard Torres, one of the study's investigators. Experimental models of gouty inflammation have shown that neutrophil influx in response to ...

Fig. 1 | The NLRP3 inflammasome is an upstream activator of IL-1β and IL-18. NodThera is employing novel chemistry to create small molecules that inhibit the NLRP3 inflammasome that have now ...

The researchers have now discovered that a special "sensor" in the cells, known as NLRP3, is activated when ... processes play a role—such as gout, type 2 diabetes or severe cases of COVID ...

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

Once again, NASH was trumpeted as the primary focus of that deal, along with gout and atherosclerosis. Other companies active in the NLRP3 category include NodThera, which has a lead candidate ...